Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment

Recruiting Observational Study
Coronary Arterial Disease (CAD)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 75
Sex
Any
Study type
Observational
Participants needed
961 (estimated)
Sponsor
Fondazione Toscana Gabriele Monasterio · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Current medical treatments, in patients with stable coronary artery disease (CAD), mainly target established risk factors and are able to reduce morbidity and mortality but still leave a substantial residual risk of coronary artery disease progression and events. The main hypothesis of this study is that metabolic derangement, including pre-diabetes, elevated levels of triglycerides, low levels an…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
RETROSPECTIVE STUDY Inclusion Criteria: * patients with known or suspected stable CAD who underwent CCT for the registered studies "SMARTool" or "Studio di biomarcatori in vivo ed in vitro" * fully accessible CCT image files and whole blood and plasma/serum aliquots stored in BioBank * written inf…
Contacts

Danilo Neglia, MD, PhD

+393355857594

dneglia@ftgm.it

CONTACT

Maria Sole Morelli, PhD

+393498337562

msmorelli@ftgm.it

CONTACT